Recent Updates
Recently added Catalysts
ANTX Negative Sentiment Score: 20/100

AN2 Therapeutics Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm

Key Takeaway: Block & Leviton is investigating AN2 Therapeutics for potential securities law violations following a significant drop in share price. The firm's investigation was prompted by the company's announcement of a pause in Phase 3 enrollment of its clinical trial for epetraborole, which saw shares decline over 70% in premarket trading. Investors who have incurred losses are encouraged to contact Block & Leviton to learn about possible recovery of their investments. The situation raises concerns for investors regarding the company's compliance with securities regulations.

Market Sentiment Analysis

CONCERNS & RISKS

  • Investors have lost significant money due to a 70% drop in shares.
  • AN2 Therapeutics has paused Phase 3 enrollment in a critical clinical trial.
  • The investigation into potential securities law violations suggests serious issues.

Full Press Release Details

BOSTON, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Block & Leviton is investigating AN2 Therapeutics, Inc. (NASDAQ: ANTX) for potential securities law violations. Investors who have lost money in their AN2 Therapeutics, Inc. investment should contact the firm to learn more about how they might recover those losses. For more details, visit https://www.blockleviton.com/cases/antx.
What is this all about?
Before the market open on February 12, 2024, AN2 Therapeutics announced a pause in Phase 3 enrollment in its seamless Phase 2/3 clinical trial (EBO-301) evaluating epetraborole in treatment-refractory MAC lung disease, pending further data review.
Shares of AN2 Therapeutics stock dropped more than 70% in premarket trading on February 12, 2024.
Anyone who purchased AN2 Therapeutics, Inc. common stock and has seen their shares fall may be eligible, whether or not they have sold their investment. Investors should contact Block & Leviton to learn more.
What is Block & Leviton doing?
Block & Leviton is investigating whether the Company committed securities law violations and may file an action to attempt to recover losses on behalf of investors who have lost money.
What should you do next?
If you've lost money on your investment, you should contact Block & Leviton to learn more via our case website, by email at cases@blockleviton.com, or by phone at (617) 398-5600.
Why should you contact Block & Leviton?
Block & Leviton is widely regarded as one of the leading securities class action firms in the country. Our attorneys have recovered billions of dollars for defrauded investors and are dedicated to obtaining significant recoveries on behalf of our clients through active litigation in the federal courts across the country. Many of the nation's top institutional investors hire us to represent their interests. You can learn more about us at our website, www.blockleviton.com, or call (617) 398-5600 or email cases@blockleviton.com with any questions.
This notice may constitute attorney advertising.
260 Franklin St., Suite 1860
Phone: (617) 398-5600
SOURCE: Block & Leviton LLP

Tags

Frequently Asked Questions

What violations is Block & Leviton investigating?

Block & Leviton is investigating AN2 Therapeutics for potential securities law violations.

What happened to AN2 Therapeutics stock?

AN2 Therapeutics stock dropped over 70% after announcing a pause in clinical trial enrollment.

Who can contact Block & Leviton?

Any investor who lost money on AN2 Therapeutics, regardless of whether they sold their shares.

How can I contact Block & Leviton?

You can reach Block & Leviton via their website, email, or by phone for assistance.

Why choose Block & Leviton for legal help?

They are a leading securities class action firm with a track record of recovering billions for investors.

Last updated: Feb 12, 2024